-
1.Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis 有权
标题翻译: 用于治疗高增殖性疾病和与血管生成有关的疾病的2,3-二氢咪唑并[1,2-c]喹唑啉衍生物公开(公告)号:US08466283B2
公开(公告)日:2013-06-18
申请号:US12517875
申请日:2007-12-05
申请人: Martin Hentemann , Jill Wood , William Scott , Martin Michels , Ann-Marie Campbell , Ann-Marie Bullion , Bruce R. Rowley , Aniko Redman
发明人: Martin Hentemann , Jill Wood , William Scott , Martin Michels , Ann-Marie Campbell , Ann-Marie Bullion , Bruce R. Rowley , Aniko Redman
IPC分类号: C07D491/00
CPC分类号: A61K31/5377 , A01N43/90 , A61K31/519 , C07D487/04
摘要: This invention relates to novel 2,3-dihydroimidazo[1,2-c]quinazoline compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for phosphotidylinositol-3-kinase (PI3K) inhibition and treating diseases associated with phosphotidylinositol-3-kinase (PI3K) activity, in particular treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients.
摘要翻译: 本发明涉及新的2,3-二氢咪唑并[1,2-c]喹唑啉化合物,含有这些化合物的药物组合物以及这些化合物或组合物用于磷脂酰肌醇-3-激酶(PI3K)抑制和治疗与磷脂酰肌醇 - 3-激酶(PI3K)活性,特别是治疗高增殖和/或血管生成障碍,作为唯一的药剂或与其它活性成分组合。
-
2.INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS 审中-公开
标题翻译: 使用取代的杂环类抗生素抑制P38激酶活性公开(公告)号:US20120149706A1
公开(公告)日:2012-06-14
申请号:US13401272
申请日:2012-02-21
申请人: Jacques DUMAS , Uday KHIRE , Timothy B. Lowinger , Holger PAULSEN , Bernd RIEDL , Willian J. SCOTT , Roger A. SMITH , Jill WOOD , Holia HATOUM-MOKDAD , Wendy LEE , Aniko REDMAN , Jeffrey JOHNSON , Robert SIBLEY
发明人: Jacques DUMAS , Uday KHIRE , Timothy B. Lowinger , Holger PAULSEN , Bernd RIEDL , Willian J. SCOTT , Roger A. SMITH , Jill WOOD , Holia HATOUM-MOKDAD , Wendy LEE , Aniko REDMAN , Jeffrey JOHNSON , Robert SIBLEY
IPC分类号: A61K31/42 , C07D413/12 , A61K31/4439 , A61K31/497 , A61K31/506 , A61P37/06 , A61P29/00 , A61P37/02 , A61P19/10 , A61P19/02 , A61P11/06 , A61P1/00 , C07D261/14 , A61K31/5377
CPC分类号: C07D231/40 , A61K31/381 , A61K31/415 , A61K31/4155 , A61K31/416 , A61K31/42 , A61K31/421 , A61K31/422 , A61K31/426 , A61K31/428 , A61K31/4436 , A61K31/4439 , A61K31/444 , A61K31/4709 , A61K31/506 , C07D261/14 , Y02A50/411
摘要: This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases, other than cancer and proteolytic enzyme mediated diseases, other than cancer, and pharmaceutical compositions for use in such therapy.
摘要翻译: 本发明涉及一组芳基脲处理细胞因子介导的疾病,除了癌症以外的癌症和蛋白水解酶介导的疾病,以及用于这种治疗的药物组合物。
-
3.2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer 有权
标题翻译: 2- [2- {苯基氨基} -1H-吡咯并[2,3-D]嘧啶-4-基)氨基]苯甲酰胺衍生物作为治疗癌症的IGF-1R抑制剂公开(公告)号:US07981903B2
公开(公告)日:2011-07-19
申请号:US12671960
申请日:2008-08-06
申请人: Stanley Dawes Chamberlain , Felix Deanda, Jr. , Roseanne Gerding , Masaichi Hasegawa , Kevin Kuntz , Huangshu Lei , Yasushi Miyazaki , Naohiko Nishigaki , Samarjit Patnaik , Aniko Redman , John Brad Shotwell , Kirk Stevens , Joseph Wilson , Bin Yang
发明人: Stanley Dawes Chamberlain , Felix Deanda, Jr. , Roseanne Gerding , Masaichi Hasegawa , Kevin Kuntz , Huangshu Lei , Yasushi Miyazaki , Naohiko Nishigaki , Samarjit Patnaik , Aniko Redman , John Brad Shotwell , Kirk Stevens , Joseph Wilson , Bin Yang
IPC分类号: A01N43/90 , A61K31/519 , C07D487/00
CPC分类号: C07D487/04 , C07D487/14
摘要: Novel pyrrolopyrimidines as shown in formula (I): and pharmaceutically acceptable derivatives thereof. The compounds are useful in the inhibition of IGF-1R.
摘要翻译: 式(I)所示的新型吡咯并嘧啶及其药学上可接受的衍生物。 该化合物可用于抑制IGF-1R。
-
4.Substituted 2,3-dihydroimidazo[1,2-c]quinazoline Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis 有权
标题翻译: 取代的2,3-二氢咪唑并[1,2-c]喹唑啉衍生物可用于治疗与血管发生相关的超增殖性疾病和疾病公开(公告)号:US20110083984A1
公开(公告)日:2011-04-14
申请号:US12517875
申请日:2007-12-05
申请人: Martin Hentemann , Jill Wood , William Scott , Martin Michels , Ann-Marie Campbell , Ann-Marie Bullion , Bruce R. Rowley , Aniko Redman
发明人: Martin Hentemann , Jill Wood , William Scott , Martin Michels , Ann-Marie Campbell , Ann-Marie Bullion , Bruce R. Rowley , Aniko Redman
IPC分类号: B65D85/00 , C12N9/99 , A61K31/5377 , A61K31/519 , C07D487/04 , A61P35/00 , A61P29/00 , A61P3/00 , A61P9/00 , A61P7/02
CPC分类号: A61K31/5377 , A01N43/90 , A61K31/519 , C07D487/04
摘要: This invention relates to novel 2,3-dihydroimidazo[1,2-c]quinazoline compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for phosphotidylinositol-3-kinase (PI3K) inhibition and treating diseases associated with phosphotidylinositol-3-kinase (PI3K) activity, in particular treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients.
摘要翻译: 本发明涉及新的2,3-二氢咪唑并[1,2-c]喹唑啉化合物,含有这些化合物的药物组合物以及这些化合物或组合物用于磷脂酰肌醇-3-激酶(PI3K)抑制和治疗与磷脂酰肌醇 - 3-激酶(PI3K)活性,特别是治疗高增殖和/或血管生成障碍,作为唯一的药剂或与其它活性成分组合。
-
5.INHIBITION OF RAF KINASE USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS 失效
标题翻译: 使用ARYL和HETEROARYL取代的杂环类URAAS对RAF激酶的抑制作用公开(公告)号:US20080009527A1
公开(公告)日:2008-01-10
申请号:US11768533
申请日:2007-06-26
申请人: Jacques Dumas , Uday Khire , Timothy Lowinger , Bernard Riedl , William Scott , Roger Smith , Jill Wood , Holia Hatoum-Mokdad , Jeffrey Johnson , Aniko Redman , Robert Sibley
发明人: Jacques Dumas , Uday Khire , Timothy Lowinger , Bernard Riedl , William Scott , Roger Smith , Jill Wood , Holia Hatoum-Mokdad , Jeffrey Johnson , Aniko Redman , Robert Sibley
IPC分类号: A61K31/4439 , A61K31/415 , A61P35/00 , C07D401/12 , C07D405/04 , C07D231/38 , A61K31/443
CPC分类号: C07D231/40 , C07D333/36 , C07D401/12 , C07D405/04
摘要: Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se,
摘要翻译: 用raf激酶介导的肿瘤治疗方法,用取代的脲化合物和这些化合物本身,
-
6.
公开(公告)号:US20070244120A1
公开(公告)日:2007-10-18
申请号:US11768112
申请日:2007-06-25
申请人: Jacques Dumas , Uday Khire , Timothy Lowinger , Holger Paulsen , Bernd Riedl , William Scott , Roger Smith , Jill Wood , Holia Hatoum-Mokdad , Jeffrey Johnson , Wendy Lee , Aniko Redman , Robert Sibley , Joel Renick
发明人: Jacques Dumas , Uday Khire , Timothy Lowinger , Holger Paulsen , Bernd Riedl , William Scott , Roger Smith , Jill Wood , Holia Hatoum-Mokdad , Jeffrey Johnson , Wendy Lee , Aniko Redman , Robert Sibley , Joel Renick
IPC分类号: A61K31/5377 , A61K31/09 , A61K31/136 , A61K31/381 , A61K31/4164 , A61K31/4196 , A61K31/42 , A61K31/426 , C07D401/12 , C07D231/10 , A61K31/44 , A61K31/4427 , A61K31/4439 , A61K31/4709 , A61K31/496 , A61K31/497
CPC分类号: C07D231/40 , C07D207/34 , C07D259/00 , C07D261/14 , C07D271/113 , C07D285/135 , C07D333/36 , C07D401/12 , C07D409/12 , C07D413/12 , C07D417/12
摘要: Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.
摘要翻译: 治疗由raf激酶介导的肿瘤与取代的脲化合物及其化合物本身的方法。
-
7.SULFONE SUBSTITUTED 2,3-DIHYDROIMIDAZO [1,2-C] QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES WITH ANGIOGENESIS 有权
标题翻译: SULFONE取代的2,3-二羟基喹喔啉[1,2-C]喹唑啉衍生物有助于治疗高血压疾病和疾病与血管发生公开(公告)号:US20110190281A1
公开(公告)日:2011-08-04
申请号:US12812911
申请日:2009-01-13
申请人: Martin Hentemann , William Scott , Jill Wood , Jeffrey Johnson , Aniko Redman , Ann-Marie Bullion , Leatte Guernon
发明人: Martin Hentemann , William Scott , Jill Wood , Jeffrey Johnson , Aniko Redman , Ann-Marie Bullion , Leatte Guernon
IPC分类号: A61K31/541 , C07D487/04 , A61K31/519 , C12N9/99 , C07D413/14 , A61K31/5377 , C07D417/14 , A61P35/00
CPC分类号: A61K45/06 , A61K31/519 , A61K31/541 , A61K2300/00 , C07D487/04
摘要: This invention relates to novel sulfone 2I3-dihydroimidazo[1,2-c]quinazoline compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for phosphotidylinositol-3-kinase (PI3K) inhibition and treating diseases associated with phosphotidylinositol-3-kinase (PI3K) activity, in particular treating hyper-proliferative and/or angiogenesis mediated disorders, as a sole agent or in combination with other active ingredients.
摘要翻译: 本发明涉及新的砜2I3-二氢咪唑并[1,2-c]喹唑啉化合物,含有这些化合物的药物组合物,以及这些化合物或组合物用于磷脂酰肌醇-3-激酶(PI3K)抑制和治疗与磷脂酰肌醇-3 - 激酶(PI3K)活性,特别是治疗高增殖和/或血管发生介导的病症,作为唯一的药剂或与其它活性成分组合。
-
8.2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer 有权
标题翻译: 2- [2- [1H-吡咯并[2,3-D]嘧啶-4-基)氨基]苯甲酰胺衍生物作为IGF-1R抑制剂治疗癌症公开(公告)号:US20100204196A1
公开(公告)日:2010-08-12
申请号:US12671960
申请日:2008-08-06
申请人: Stanley Dawes Chamberlain , Felix Deanda, JR. , Roseanne Gerding , Masaichi Hasegawa , Kevin Kuntz , Huangshu Lei , Yasushi Miyazaki , Naohiko Nishigaki , Samarjit Patnaik , Aniko Redman , John Brad Shotwell , Kirk Stevens , Joseph Wilson , Bin Yang
发明人: Stanley Dawes Chamberlain , Felix Deanda, JR. , Roseanne Gerding , Masaichi Hasegawa , Kevin Kuntz , Huangshu Lei , Yasushi Miyazaki , Naohiko Nishigaki , Samarjit Patnaik , Aniko Redman , John Brad Shotwell , Kirk Stevens , Joseph Wilson , Bin Yang
IPC分类号: A61K31/397 , C07D487/04 , A61K31/519 , A61K31/496 , A61K31/5377 , A61K31/551 , A61P35/00
CPC分类号: C07D487/04 , C07D487/14
摘要: Novel pyrrolopyrimidines as shown in formula (I): and pharmaceutically acceptable derivatives thereof. The compounds are useful in the inhibition of IGF-1R.
摘要翻译: 式(I)所示的新型吡咯并嘧啶及其药学上可接受的衍生物。 该化合物可用于抑制IGF-1R。
-
9.Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas 审中-公开
标题翻译: 使用芳基和杂芳基取代的杂环脲抑制p38激酶活性公开(公告)号:US20080300281A1
公开(公告)日:2008-12-04
申请号:US12181032
申请日:2008-07-28
申请人: Jacques Dumas , Uday Khire , Timothy B. Lowinger , Bernd Riedl , William J. Scott , Roger A. Smith , Jill E. Wood , Holia Hatoum-Mokdad , Jeffrey Johnson , Aniko Redman , Robert Sibley
发明人: Jacques Dumas , Uday Khire , Timothy B. Lowinger , Bernd Riedl , William J. Scott , Roger A. Smith , Jill E. Wood , Holia Hatoum-Mokdad , Jeffrey Johnson , Aniko Redman , Robert Sibley
IPC分类号: A61K31/4439 , A61K31/415 , A61K31/4427 , A61K31/381 , A61P19/02
CPC分类号: A61K31/381 , A61K31/415 , A61K31/4427 , A61K31/4439 , Y02A50/411
摘要: This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases other than cancer and proteolytic enzyme mediated diseases other than cancer, and pharmaceutical compositions for use in such therapy.
摘要翻译: 本发明涉及一组芳基脲在治疗癌症以外的细胞因子介导的疾病和除了癌症以外的蛋白水解酶介导的疾病以及用于这种治疗的药物组合物中的用途。
-
10.
公开(公告)号:US20080293696A1
公开(公告)日:2008-11-27
申请号:US11630850
申请日:2005-06-23
申请人: Catherine Brennan , Julie A. Dixon , William J. Scott , Aniko Redman , Benjamin D. Jones , Barton Phillips , Philip Wickens , Istvan Enyedy , Ellalahewage Kumarasinghe , Charles Kreiman , Jacques Dumas , Uday Khire , Chih-Yuan Chuang , Harold C.E. Kluender , Zhenqiu Hong , Lei Wang , Donald Bierer
发明人: Catherine Brennan , Julie A. Dixon , William J. Scott , Aniko Redman , Benjamin D. Jones , Barton Phillips , Philip Wickens , Istvan Enyedy , Ellalahewage Kumarasinghe , Charles Kreiman , Jacques Dumas , Uday Khire , Chih-Yuan Chuang , Harold C.E. Kluender , Zhenqiu Hong , Lei Wang , Donald Bierer
IPC分类号: A61K31/55 , C07D405/12 , A61K31/4433 , A61K31/444 , A61P35/00 , C07D405/14 , A61K31/506
CPC分类号: C07D319/08
摘要: A compound having the formula (1) in which the ring containing E is a phenyl, a pyridine, or a pyrimidine. In formula (1) the symbol A represents wherein the group R4 represents halogen, CF3, or H, provided that the maximum number of CF3 groups on any A is 2, and the maximum number of hydrogens on A is 2 for the A groups which together with the carbon atoms to which they are attached form 6-membered rings, and the maximum number of hydrogens on A is 1 for the A group which together with the carbon atoms to which it is attached forms a 5-membered ring. Z represents N or CH when E forms a phenyl ring, and represents CH when E forms a pyridine or pyrimidine. The groups R1, R2 and R3 and the subscripts a, b, and d are as defined in the text and claims. Pharmaceutical compositions containing a compound of formula (1) and methods of treating cancer using compounds of formula (1) are also disclosed and claimed.
摘要翻译: 具有式(1)的化合物,其中含有E的环是苯基,吡啶或嘧啶。 在式(1)中,符号A表示其中基团R 4表示卤素,CF 3或H,条件是任何A上的CF 3基团的最大数目为2,并且A组中的最大氢数为2, 与它们连接的碳原子一起形成6元环,并且对于与连接的碳原子一起形成5元环的A基团,A上的最大氢数为1。 当E形成苯环时,Z表示N或CH,当E形成吡啶或嘧啶时,Z表示CH。 基团R1,R2和R3以及下标a,b和d如本文和权利要求中所定义。 还公开并要求保护含有式(1)化合物的药物组合物和使用式(1)化合物治疗癌症的方法。
-
-
-
-
-
-
-
-
-